Biomedical Engineering Reference
In-Depth Information
80. Allen, M.R., Burr, D.B. Mineralization, microdamage, and matrix: how bisphosphonates
influence material properties of bone. BoneKEy 2007;4:49-60;
http://www.bonekey-ibms.
81. Stepan, J.J., Burr, D.B., Pavo, I., Sipos, A., Michalska, D., Li, J., Fahrleitner-Pammer, A.,
Petto, H., Westmore, M., Michalsky, D., Sato, M., Dobnig, H.: Low bone mineral density is
associated
with
bone
microdamage
accumulation
in
postmenopausal
women
with
osteoporosis. Bone 41, 378-385 (2007)
82. Chapurlat, R.D., Arlot, M., Burt-Pichat, B., Chavassieux, P., Roux, J.P., Portero-Muzy, N.,
Delmas, P.D.: Microcrack frequency and bone remodeling in postmenopausal osteoporotic
women on long-term bisphosphonates: a bone biopsy study. J. Bone Miner. Res. 22, 1502-
1509 (2007)
83. Diab, T., Condon, K.W., Burr, D.B., Vashishth, D.: Age-related change in the damage
morphology of human cortical bone and its role in bone fragility. Bone 38, 427-431 (2006)
84. Norman, T.L., Wang, Z.: Microdamage of human cortical bone: incidence and morphology
in long bones. Bone 20, 375-379 (1997)
85. Schaffler, M.B., Choi, K., Milgrom, C.: Aging and matrix microdamage accumulation in
human compact bone. Bone 17, 521-525 (1995)
86. Komatsubara, S., Mori, S., Mashiba, T., Ito, M., Li, J., Kaji, Y., Akiyama, T., Miyamoto, K.,
Cao, Y., Kawanishi, J., Norimatsu, H.: Long-term treatment of incadronate disodium
accumulates microdamage but improves the trabecular bone microarchitecture in dog
vertebra. J. Bone Miner. Res. 18, 512-520 (2003)
87. Sellmeyer, D.E., Black, D.M., Palermo, L., Greenspan, S., Ensrud, K., Bilezikian, J., Rosen, C.J.:
Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of
osteoporosis. Osteoporos. Int. 18, 973-979 (2007)
88. Greenspan, S.L., Bone, H.G., Ettinger, M.P., Hanley, D.A., Lindsay, R., Zanchetta, J.R.,
Blosch, C.M., Mathisen, A.L., Morris, S.A., Marriott, T.B.: Effect of recombinant human
parathyroid hormone(1-84) on vertebral fracture and bone mineral density in
postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med. 146,
326-339 (2007)
89. Recker, R.R., Bare, S.P., Smith, S.Y., Varela, A., Miller, M.A., Morris, S.A., Fox, J.:
Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal
osteoporotic women treated with parathyroid hormone1-84. Bone 44, 113-119 (2009)
90. Hodsman, A.B., Fraher, L.J., Ostbye, T., Adachi, J.D., Steer, B.M.: An evaluation of several
biochemical markers for bone formation and resorption in a protocol utilizing cyclical
parathyroid hormone and calcitonin therapy for osteoporosis. J. Clin. Invest. 91, 1138-1148
(1993)
91. Hodsman, A.B., Kisiel, M., Adachi, J.D., Fraher, L.J., Watson, P.H.: Histomorphometric
evidence for increased bone turnover without change in cortical thickness or porosity after
2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. Bone 27, 311-
318 (2000)
92. Lindsay, R., Nieves, J., Formica, C., Henneman, E., Woelfert, L., Shen, V., Dempster, D.,
Cosman, F.: Randomised controlled study of effect of parathyroid hormone on vertebral-
bone mass and fracture incidence among postmenopausal women on oestrogen with
osteoporosis. Lancet 350, 550-555 (1997)
93. Burr, D.B.: Does early PTH treatment compromise bone strength? The balance between
remodeling, porosity, bone mineral, and bone size. Curr. Osteoporos. Rep. 3, 19-24 (2005)
94. Rubin,
M.R.,
Bilezikian,
J.P.:
New
anabolic
therapies
in
osteoporosis.
Curr.
Opin.
Rheumatol. 14, 433-440 (2002)
95. Ettinger, B., San Martin, J., Crans, G., Pavo, I.: Differential effects of teriparatide on BMD
after treatment with raloxifene or alendronate. J. Bone Miner. Res. 19, 745-751 (2004)
96. Prince, R., Sipos, A., Hossain, A., Syversen, U., Ish-Shalom, S., Marcinowska, E., Halse, J.,
Lindsay, R., Dalsky, G.P., Mitlak, B.H.: Sustained nonvertebral fragility fracture risk
reduction after discontinuation of teriparatide treatment. J. Bone Miner. Res. 20, 1507-1513
(2005)
Search WWH ::
Custom Search